Save time and get answers to complex questions with AI chat
Can wine consumption affect lipitor's cholesterol lowering ability?Drugpatentwatch crizotinib?When is the expected fda decision date for apotex's ruxolitinib resubmission?Patent term adjustment semaglutida?Is guselkumab off patent in u s?
See the DrugPatentWatch profile for Relyvrio
Relyvrio, a drug used to treat amyotrophic lateral sclerosis (ALS), is a modified version of the amino acid β-alanine, which is naturally found in the human body [1]. Research suggests that β-alanine has neuroprotective effects and can help slow down the progression of ALS by reducing the levels of glutamate, a neurotransmitter that may contribute to the degeneration of motor neurons [2]. When taken orally, Relyvrio is thought to increase the production of β-alanine in the body. This results in the accumulation of β-alanine in the cerebrospinal fluid and potentially leads to a reduction in glutamate levels, thereby reducing oxidative stress and inflammation associated with ALS [3]. Relyvrio's effectiveness in treating ALS is still being studied, but a clinical trial demonstrated that patients who took the drug experienced a slower decline in the rate of functional decline, as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) [4]. While more research is needed to fully understand Relyvrio's mechanism of action and long-term efficacy in treating ALS, initial findings indicate that it may represent a valuable treatment option for patients with this debilitating disease. Sources: [1] https://www.drugpatentwatch.com/patent/US10572991 [2] https://pubmed.ncbi.nlm.nih.gov/32943993/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465553/ [4] https://pubmed.ncbi.nlm.nih.gov/35934129/
Other Questions About Relyvrio :